Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats

• OKADA Tadashi

  Division of Nephrology and Blood Purification Medicine, Wakayama Medical University

• SAKAGUCHI Toshifumi

  Division of Nephrology and Blood Purification Medicine, Wakayama Medical University

• HATAMURA Ikuji

  First Department of Pathology, Wakayama Medical University

• SAJI Fumie

  Division of Nephrology and Blood Purification Medicine, Wakayama Medical University

• NEGI Shigeo

  Division of Nephrology and Blood Purification Medicine, Wakayama Medical University

• OTANI Haruhisa

  Division of Nephrology and Blood Purification Medicine, Wakayama Medical University

• MURAGAKI Yasuteru

  First Department of Pathology, Wakayama Medical University

• KAWACHI Hiroshi

  Department of Cell Biology, Institute of Nephrology, Niigata University Graduate School of Medical and Dental Sciences

• SHIGEMATSU Takashi

  Division of Nephrology and Blood Purification Medicine, Wakayama Medical University

Journal

• Clinical and experimental nephrology

  Clinical and experimental nephrology 13 (5), 438-446, 2009-10-01

Keywords

• Vasopression
• Podocyte
• Tolvaptan
• Puromycin
• V2 antagonist

Details

• CRID: 1574231875934342144
• NII Article ID: 10027226471
• NII Book ID: AA11126935
• ISSN: 13421751
• Text Lang: en
• Data Source:
  • CiNii Articles